靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2024-09-20 |
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
100 项与 Zevra Denmark A/S 相关的临床结果
0 项与 Zevra Denmark A/S 相关的专利(医药)
100 项与 Zevra Denmark A/S 相关的药物交易
100 项与 Zevra Denmark A/S 相关的转化医学